🔴 Milestone Pharmaceuticals is trading 5% down as specific catalyst remains unclear

Milestone Pharmaceuticals is trading 5.16% down at $0.72, with no company-specific announcement explaining the decline found for October 8.

• The latest listed company release was September 24, about starting a Phase 3 trial.
• Reports cited renewed Middle East tensions, rising oil prices and elevated Treasury yields as weighing on global equities. Reporting did not establish a direct link to the stock’s move, so the specific catalyst remains unclear.